Home
About Us
Conditions & Procedures
Conditions
Procedures
Faculty
Patient Resources
Research
News & Events
Make a Gift
A gift to the UCSF Department of Surgery can help physicians and scientist find treatments and cures for serious liver diseases such as hepatitis B & C, and liver cancer.
Alexander R. Gottschalk, M.D., Ph.D.
Associate Professor
Director of the CyberKnife Radiosurgery Program
Department of Radiation Oncology
Contact Information
Box 1708, 1600 Divisadero St, MZ Bldg R H1031
San Francisco, CA. 94143 - 1708
Phone: 415-353-7175
Fax 415-353-9883
agottschalk@radonc.ucsf.edu
BiographyEducation
- 1988 University of Chicago BA Chemistry
- 1994 University of Chicago PhD Pathology
- 1996 University of Chicago MD Medicine
- 1996-1997 Kaiser Permanente Medical Center, Santa Clara, CA Intern Internal Medicine
- 1997-2001 UCSF Resident Radiation Oncology
- 01/00-04/00 UCSF Chief Resident Radiation Oncology
Residencies
- 1997-2001 UCSF Residency in Radiation Oncology
- 1996-1997 Kaiser Internal Medicine Internship
Board Certification
- American Board of Radiology
Program Affiliations
- Department of Radiation Oncology
- Helen Diller FamilyComprehensive Cancer Center
- Sarcoma Program
- Thoracic Oncology Program
Clinical Expertise
- Brain and Spinal Tumors
- Bronchioloalveolar Carcinoma (BAC)
- CyberKnife Irradiation for Lung and Skull Base
- Esophageal Cancer
- External-beam Radiation
- Intensity-modulated radiation therapy (IMRT)
- Non-Small Cell Lung Cancer
- Sarcoma
- Small-Cell Lung Cancer
- Stereotactic Lung Radiotherapy (SBRT)
Research Interests
- Image-guided and adaptive radiation therapy
- Radiation in combination with chemotherapy and targeted agents
- Radiation sensitizers and protectors
Biography
Dr. Alexander Gottschalk, an expert in radiation treatment, is director of the UCSF Cyberknife Radiosurgery Program. Using the Cyberknife, Gottschalk treats cancer of the brain and spine; breast, chest and lung; abdomen; kidney; and pelvis. In addition, he treats urologic cancer such as bladder and prostate cancer; gastrointestinal cancer such as pancreas cancer; soft tissue tumors such as sarcoma and thoracic cancer such as lung cancer, using other radiation treatments.
Gottschalk earned a medical degree and Ph.D. at the University of Chicago and completed a residency in radiation oncology at UCSF Medical Center. He is the recipient of numerous awards and grants, including the National Institutes of Health National Research Service Award, Medical Scientist Training Program Fellowship, UCSF Helen Diller Family Comprehensive Cancer Center Clinical Investigator Research Program Grant, the RSNA Scholar award and the ASTRO Junior faculty award. He is an associate professor of radiation oncology at UCSF and active in genitourinary research. He is developing clinical trials using inter-operative.
Research Summary
Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT).
Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures.
Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer.
Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.
Clinical Trials
Selected Publications
- Gottschalk AR, Joseph LJ, Quintáns J. Differential induction of Egr-1 expression in WEHI-231 sublines does not correlate with apoptosis. European Journal of Immunology 23(8): 2011-2015, 1993.
- Gottschalk AR, McShan CL, Merino R, Nuñez G, Quintáns J. Physiological cell death in B lymphocytes: I. Differential susceptibility of WEHI-231 sublines to anti-Ig induced physiological cell death and lack of correlation with bcl-2 expression. International Immunology 6(1): 121-130, 1994.
- Gottschalk AR, Joseph LJ, Quintáns J. FcgRII cross-linking inhibits anti-Ig-induced egr-1 and egr-2 expression in BCL1. Journal of Immunology 152(5): 2115-2122, 1994.
- Gottschalk AR, Boise LH, Thompson CB, Quintáns J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proceedings of the National Academy of Sciences of the United States of America 91(15): 7350-7354, 1994.
- Quintáns J, Kilkus J, McShan CL, Gottschalk AR, Dawson G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochemical and Biophysical Research Communications 202(2): 710-714, 1994.
